ZunyouWu : Monkeypox epidemic will not cause large-scale epidemic in China.
The global threat of the new coronavirus has not been eliminated, and the monkeypox virus has attracted the attention of various countries.
According to jwview reports, on July 25, ZunyouWu , chief epidemiologist of the Chinese Center for Disease Control and Prevention, posted on micro-blog that the monkeypox epidemic will not cause a large-scale epidemic in China.
ZunyouWu pointed out that due to the limitation of the mode of transmission, the speed of its spread and the range of people affected are far from that of the COVID-19. In other words, the Monkeypox Vrius outbreak will not cause a massive epidemic in our country.
According to reports, at the same time,ZunyouWu introduced preventive measures for the monkeypox virus. He said that to prevent monkeypox, First,we must avoid contact with infected animals, and second, as far as possible, avoid direct contact with infected people. According to the main mode of transmission of this monkeypox epidemic, avoiding close contact with people who may come from the epidemic area is an important preventive measure.
In addition, there is a certain degree of cross-protection against monkeypox virus in those who have been vaccinated against smallpox in the past. Previous studies in monkeypox-endemic areas in Africa have shown that the smallpox vaccine is about 85% effective in preventing the Monkeypox Vrius.
In the news, the General Administration of Customs issued an announcement today on preventing the introduction of monkeypox epidemics into my country. Persons from countries with monkeypox epidemics who have been exposed to monkeypox cases or had fever, headache, muscle aches, back pain, swollen lymph nodes, If you have symptoms such as rashes and a large area of the body, you should take the initiative to declare to the customs when you enter the country, and the customs health and quarantine personnel will take medical measures and carry out sampling and testing according to the prescribed procedures.
In addition, a number of biopharmaceutical companies have begun to develop related monkeypox detection reagents.
The Titanium App reported on July 11, Mingde Bio said on the interactive platform that the company’s overseas sales are mainly antigen detection reagents, supplemented by the COVID-19 nucleic acid test reagents , and the main sales areas of the COVID-19 antigen detection reagents are Germany, France, Austria, etc. In Europe countries, as well as Vietnam, Malaysia and other countries in Southeast Asia. The main sales regions of the COVID-19 nucleic acid detection reagents are South Africa, Germany and other countries. According to the Investor Relations Activity Record Form dated May 11, 2022, the company's overseas sales in the first quarter of 2022 accounted for approximately 12% of operating income.
